Jyong Biotech Ltd. (JYB)
Jyong Biotech will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Company Description

Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China).

Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms.

PCP, our key new drug candidate developed for the prevention of prostate cancer, is under phase II trials stage in Taiwan.

Another preclinical-stage key drug candidate, IC, is under preclinical studies for the treatment of interstitial cystitis.

Jyong Biotech Ltd.
Country Taiwan
Founded 2002
Industry Biotechnology
Sector Healthcare
Employees 31
CEO Fu-Feng Kuo

Contact Details

Address:
23F-3, No. 95, Section 1, Xintai 5th Road
Xizhi District, New Taipei City 221
Taiwan
Phone +886-2-2732-5205
Website healtheverbiotech.com

Stock Details

Ticker Symbol JYB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001954488
SIC Code 2834

Key Executives

Name Position
Fu-Feng Kuo Chairwoman of the Board of Directors and Chief Executive Officer
Fenglin Hsu Director Nominee and Chief Technology Officer Nominee
Hung-Shu Fan Independent Director Nominee
Pang-Chief Chi Independent Director Nominee
Ming Tsan Hsu Independent Director Nominee
Alfred Ying Chief Financial Officer Nominee
Wanwen (Angela) Su Chief Science Officer Nominee

Latest SEC Filings

Date Type Title
Dec 19, 2024 F-1/A [Amend] Registration statement for certain foreign private issuers
Nov 21, 2024 F-1/A [Amend] Registration statement for certain foreign private issuers
Nov 1, 2024 F-1/A [Amend] Registration statement for certain foreign private issuers
Oct 4, 2024 F-1/A [Amend] Registration statement for certain foreign private issuers
Sep 16, 2024 F-1/A [Amend] Registration statement for certain foreign private issuers
Aug 2, 2024 F-1/A [Amend] Registration statement for certain foreign private issuers
Jun 21, 2024 F-1/A [Amend] Registration statement for certain foreign private issuers
May 8, 2024 F-1/A [Amend] Registration statement for certain foreign private issuers
Mar 7, 2024 F-1 Registration statement for certain foreign private issuers
Dec 20, 2023 RW Filing